Converge Bio

The Generative AI Lab for the Life Sciences

Tel Aviv, Israel · Founded 2024 · $30.5M raised

Headquarters
Tel Aviv
Employees
11–50
Founded
2024
Business Model
B2B
Total Funding
$30.5M
Last Round
$25.0M Series AJan 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 6 investors for this company. The full record is or through the API.

About

Converge Bio is an AI-driven drug discovery company founded in 2024 and headquartered in Tel Aviv, Israel with a presence in Boston, Massachusetts. The company provides a generative AI lab for life sciences, helping pharmaceutical and biotech customers accelerate drug development through AI-powered molecule design, discovery, and manufacturing optimization. Founded by CEO Dov Gertz, CTO Oded Kalev, and CSO Iddo Weiner, Converge Bio raised a $5.5M seed in 2024 and a $25M Series A in January 2026 led by Bessemer Venture Partners. The company has completed over 40 programs with more than a dozen pharma and biotech clients globally.

Summary

Converge Bio is an Artificial Intelligence company based in Tel Aviv, Israel, founded in 2024. It has raised $30.5M in total across 2 rounds, most recently a $25.0M Series A round in Jan 2025. Investors include TLV Partners, Bessemer Venture Partners and Vintage Capital.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AJan 2025
$25.0M

Sign up to see all 2 events

Funding: Seed through Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Isomorphic Labs

AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...

London, United Kingdom201–500Artificial Intelligence, Biotech
Series BTotal funding$2.6BMay 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech, Healthcare
Corporate RoundTotal funding$2.3BJun 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Converge Bio on Indexed.vc
<a href="https://indexed.vc/companies/converge-bio"><img src="https://indexed.vc/api/badge/company/converge-bio" alt="Converge Bio on Indexed.vc" width="260" height="76" /></a>